ARTV Strangle Strategy

ARTV (Artiva Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

ARTV (Artiva Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $563.7M, a beta of 2.18 versus the broader market, a 52-week range of 2.22-14.53, average daily share volume of 527K, a public-listing history dating back to 2024, approximately 106 full-time employees. These structural characteristics shape how ARTV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.18 indicates ARTV has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on ARTV?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

ARTV snapshot

As of August 14, 2026, spot at $11.54, ATM IV 154.20%, expected move 44.21%. The strangle on ARTV below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this strangle structure on ARTV specifically: IV rank is unavailable in the current snapshot, so regime-based timing for ARTV is inferred from ATM IV at 154.20% alone, with a market-implied 1-standard-deviation move of approximately 44.21% (roughly $5.10 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARTV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARTV should anchor to the underlying notional of $11.54 per share and to the trader's directional view on ARTV stock.

ARTV strangle setup

The ARTV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARTV at $11.54 on that close, the first option leg uses a $12.12 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARTV chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARTV shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$12.12	N/A
Buy 1	Put	$10.96	N/A

ARTV strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ARTV strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ARTV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on ARTV

Strangles on ARTV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARTV chain.

ARTV thesis for this strangle

The market-implied 1-standard-deviation range for ARTV extends from approximately $6.44 on the downside to $16.64 on the upside. A ARTV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. As a Healthcare name, ARTV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARTV-specific events.

ARTV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARTV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARTV alongside the broader basket even when ARTV-specific fundamentals are unchanged. Always rebuild the position from current ARTV chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ARTV?: A strangle on ARTV is the strangle strategy applied to ARTV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ARTV stock at $11.54 on the most recent close, the strikes shown on this page are snapped to the nearest listed ARTV chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ARTV strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ARTV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 154.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ARTV strangle?: The breakeven for the ARTV strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ARTV market-implied 1-standard-deviation expected move in the same options snapshot is approximately 44.21%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ARTV?: Strangles on ARTV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARTV chain.
How does current ARTV implied volatility affect this strangle?: Current ARTV ATM IV is 154.20%; IV rank context is unavailable in the current snapshot.